Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an update.
RemeGen reported strong product sales revenue of about RMB2.31 billion for 2025, up 35.8% year on year, driven mainly by robust growth from its autoimmune therapy telitacicept and oncology drug disitamab vedotin. The performance underscores the company’s transition from a research-focused biotech to a commercial-stage player with growing scale in China’s innovative drug market.
Over the year, RemeGen advanced telitacicept across multiple indications, securing Chinese approval for generalized myasthenia gravis, gaining European Orphan Drug Designation, and achieving positive Phase III results in Sjögren’s syndrome and IgA nephropathy. Regulatory filings for these new indications were accepted in China, with priority review for IgA nephropathy and inclusion of telitacicept for systemic lupus erythematosus and generalized myasthenia gravis in the National Reimbursement Drug List, while an out-licensing deal with a Nasdaq-listed partner highlights its strategy to monetize global intellectual property.
The combination of strong commercial growth, expanding reimbursement coverage, and late-stage clinical successes positions RemeGen to broaden its market footprint in autoimmune diseases and enhance long-term revenue visibility. These developments may improve patient access to novel therapies, support further pipeline investment, and reinforce the company’s competitive standing in both domestic and international biopharma markets.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$82.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a China-based biopharmaceutical company focused on developing and commercializing innovative biologic therapies for autoimmune diseases and cancers. Its key commercial products include telitacicept for autoimmune indications and disitamab vedotin for tumor treatments, targeting both domestic and international markets through clinical development and licensing deals.
The company operates within the competitive global biotech sector, emphasizing antibody and fusion protein drugs and pursuing regulatory approvals and reimbursement listings in major markets. By advancing multiple late-stage clinical programs and securing inclusion in China’s National Reimbursement Drug List, RemeGen aims to strengthen its revenue base and expand patient access to its therapies.
Average Trading Volume: 4,071,402
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$65.16B
Learn more about 9995 stock on TipRanks’ Stock Analysis page.